Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Cyr61 and CTGF genes may play an important role in hepatocellular carcinogenesis and correlate with recurrence and metastasis of hepatocellular carcinoma.
|
15526358 |
2004 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyr61 and CTGF genes may play an important role in hepatocellular carcinogenesis and correlate with recurrence and metastasis of hepatocellular carcinoma.
|
15526358 |
2004 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
|
21312266 |
2011 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyr61 is known as an important player in tumor progression, promoting neovascularization and metastasis.
|
21447598 |
2011 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cyr61 and VEGF expressions moderately correlated with each other in osteosarcoma, and exhibited significant association with Enneking stage and distant metastasis.
|
28647210 |
2017 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CYR-61 is a protein that promotes human lung cancer cell metastasis and is closely related to the patient's prognosis in NSCLC.
|
30116327 |
2018 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CYR61, an angiogenic factor that participates in tumor metastasis as well as a recognized oncogene in melanoma, is shown to be confined under CPS1-IT1 overexpression in melanoma cells.
|
31111478 |
2019 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A high expression of Cyr61 was significantly associated with solid subtype, perineural invasion, vascular invasion or cancer embolus, advanced stage, recurrence, and metastasis (P<0.05).
|
21439895 |
2011 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo.
|
22048717 |
2012 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, immunohistochemistry demonstrated increased collocalization of Cyr61 and alpha(v) in metastases relative to primary tumor.
|
15737847 |
2005 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our results demonstrated that Cyr61 played an important role in the tumorigenicity and metastasis of PCa cells, which will benefit the development of therapeutic strategy for PCas.
|
18941464 |
2008 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As a new target of statins, cysteine-rich 61 (CYR61) was recently identified to promote cell migration and metastasis in osteosarcoma.
|
30466075 |
2018 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
CCN1/CYR61 overexpression resulted in reduced tumor growth and metastasis and inhibited the activity of matrix metalloproteinase-2.
|
19632997 |
2009 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cysteine-rich protein 61 (CYR61) and metastasis associated in colon cancer (MACC1) protein promoted human colorectal cancer (CRC) cell metastasis and closely related to the patient's prognosis in colorectal cancer.
|
27492459 |
2016 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cysteine-rich protein 61 (CCN1/Cyr61) has been implicated as an important mediator in the proliferation and metastasis of breast cancer.
|
28008161 |
2016 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cysteine-rich protein 61 (CCN1/CYR61) is an important marker of proliferation and metastasis in malignant melanoma, making it a potential target for melanoma treatment.
|
27665942 |
2016 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, Cyr61 may be involved in the process of tumor metastasis and progression by producing IL-6 and CRP in the EOC inflammatory microenvironment.
|
31766991 |
2019 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, knockdown of CYR61 in gastric cancer AGS cells impairs the cancer cell migration and invasion, suggesting a driver role of CYR61 in metastasis.
|
27105510 |
2016 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Molecular validation demonstrated that FGF8 fully induced nuclear localization of YAP1 and enhanced transcriptional outcomes such as the expression of CTGF and CYR61, while decreasing YAP1 expression impeded FGF-8-induced cell growth, EMT, migration and invasion, revealing that YAP1 is required for FGF8-mediated CRC growth and metastasis.
|
25473897 |
2015 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
S100 calcium binding protein A4 (S100A4) and cysteine-rich angiogenic inducer 61 (CYR61) play important roles in epithelial-mesenchymal-transition (EMT), invasion and metastasis by promoting cancer cell motility.
|
27098123 |
2016 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Significantly raised levels of Cyr61 were associated with poor prognosis (P = 0.02), nodal involvement (P = 0.03) and metastatic disease (P = 0.016).
|
15613452 |
2004 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Silencing of CYR61 from these SHH-expressing Hh activated cells blunted the malignant behavior of the tumor cells and resulted in reduced tumor vasculature and limited hematogenous metastases.
|
22056874 |
2012 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Snail/FOXK1/Cyr61 Signaling Axis Regulates the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
|
29794466 |
2018 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Targeting stiffness-induced changes in the vasculature, such as CCN1, is therefore a potential yet unappreciated mechanism to impair metastasis.
|
28694244 |
2017 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
TGFbeta in the tumor microenvironment may stimulate cancer metastases to sites such as bone by increasing Cyr61 expression and secretion.
|
16616811 |
2007 |